***NUSAP1* and *KIAA0101* downregulation by** **neo-adjuvant therapy is associated with better** **therapeutic outcome and survival in breast cancer.**

Gerardo I. Magallanes-Garzaa, b, c\*, Sandra K. Santuario-Facioa\*, Arlina F. Varela-Varelad, Servando Cardona-Huertac, e, f, Pablo Ruiz-Floresd, Jorge Haro-Santa-Cruzd, Yadira X. Perez-Paramog, Gabriela S. Gomez-Maciasc, h, Daniel Davila-Gonzaleza, e, Javier Valero-Gomeza, Gissela Borreo-Sotoi, Augusto Rojas-Martineza, j, Rocio Ortiz-Lopeza, j\*\*.

a Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud. Monterrey, Mexico.

b Tecnologico de Monterrey, Servicio de Ginecologia y Obstetricia. Tec Salud. Monterrey, Mexico.

c Tecnologico de Monterrey, Centro de Cancer de Mama, Hospital Zambrano Hellion. San Pedro Garza Garcia, Mexico.

d Universidad Autonoma de Coahuila, Centro de Investigacion Biomedica. Facultad de Medicina Unidad Torreon. Torreon, Mexico.

e Tecnologico de Monterrey, Dirección Nacional de Investigacion Clinica TecSalud. Monterrey, Mexico.

f Instituto Mexicano del Seguro Social. Unidad Medica de Alta Especialidad No. 25. Monterrey, México

g Washington State University, Pharmaceutical Sciences Department, College of Pharmacy Spokane, WA, USA.

h Universidad Autonoma de Nuevo Leon. Facultad de Medicina. Monterrey, Mexico.

i University of Texas at Austin, Department of Molecular Biosciences. Austin, TX, USA.

j Tecnologico de Monterrey, Institute for Research in Obesity. Monterrey, Mexico.

\*Magallanes-Garza GI and Santuario-Facio SK are considered first authors, as they both contributed equally to this manuscript.

**\*\*Corresponding author:** Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Ave. Morones Prieto 3000, Monterrey, N.L., Mexico, 64710. [rortizl@tec.mx](mailto:rortizl@tec.mx)

# ABSTRACT

**Purpose:** To evaluate whether changes in genomic expression that occur beginning with breast cancer (BC) diagnosis and through to tumor resection after neo-adjuvant chemotherapy (NCT) reveal biomarkers that can help in the prediction of therapeutic response and survival.

**Materials and Methods:** We determined gene expression profiles in tumor samples from 39 BC patients who showed pathologic complete response (pCR) or therapeutic failure (no pCR) after NCT (cyclophosphamide-doxorubicin/epirubicin). On the basis of unsupervised classification analysis of microarray data and interactome studies, we selected the genes *NUSAP1*, *KIAA0101*, *MME*, and *DST* for analyses of NCT response, expression in BC histologic subtypes, and presence of tumor-infiltrating lymphocytes. Finally, correlation analyzes between *NUSAP1* and *KIAA0101* (the most discriminating genes) against disease-free survival (DFS) and overall survival (OS) were performed.

**Results:** A signature of 43 genes discriminated pCR from non-pCR patients (fold change (FC) = ±3, false discovery rate (FDR) *P* value < .0298). Patients achieving pCR showed downregulation of *NUSAP1* and *KIAA0101* in tumor tissues and increased DFS and OS, while overexpression of these genes correlated with poor therapeutic response and OS. These genes are known to be involved in regulation of mitotic division.

**Conclusions:** Downregulation of *NUSAP1* and *KIAA0101* after NCT has a significant effect on tumor response to chemotherapy and patient survival.

**Keywords:** disease-free survival, *KIAA0101*, *NUSAP1*, neo-adjuvant chemotherapy treatment, neo-adjuvant treatment, overall survival, pathologic complete response, pathologic response, survival.

# Introduction

Therapeutic response and prognosis in breast cancer (BC) are affected by such factors as patient age [1], clinical stage [2], tumor histopathology, and molecular subtypes [3]. Gene expression profiles and genomic signatures performed prior to therapy can provide additional information on tumor biology, and algorithms have been developed to predict risk of relapse and survival and to define the best treatment options [4-6]. A program of genomic testing may allow for the identification of low-risk tumors associated with a favorable prognosis and as such would facilitate therapeutic decision-making for aggressive tumors that have a poor response to conventional therapies. In addition, genomic signatures can identify gene expression patterns related to chemotherapy resistance, immune system response, and tumor invasion [7-10].

Comparisons of gene expression analyses of biopsy specimens taken before and after neo-adjuvant chemotherapy treatment (NCT), may be useful to define tumor molecular adaptations to a specific chemotherapeutic agent or regime [7-10]. The pathologic complete response (pCR) in BC is defined as the absence of all invasive tumor tissue after completion of NCT cycles [11]. The achievement of pCR after NCT correlates with patient survival [12]. Alternative treatment regimens may improve survival when pCR is not achieved [13]. Comparisons of the changing patterns of gene signatures in response to chemotherapy may enable predictions of clinical response and prognosis, and sometimes, to recognize new response biomarkers of specific pathways related to treatment resistance and recurrence.

There is no genomic signature to define therapeutic alternatives in patients with incomplete pathologic response (non-pCR). Therefore, the identification of gene expression profiles in tumor tissue after NCT that are associated with a good or a bad pathological response or with survival could facilitate the identification of patients who could benefit from second-line adjuvant treatment or improve clinical follow-up, as has been shown in some studies assessing pathologic response [14]. Review of the biochemical pathways in which these genes are involved could also provide potential therapeutic targets or identify markers for high-risk patients who require closer follow-up.

The aim of this work was to analyze changes in genomic expression in primary BC tumors in patients undergoing NCT and to identify genes associated with prognosis in nonresponding patients that could guide new pharmaceutical interventions for a second line of treatment. After validation, our studies that showed downregulation of *NUSAP1* and *KIAA0101* and overexpression of *MME* and *DST* in tumor biopsies of patients correlated with pCR after NCT and significantly correlated with both disease-free survival (DFS) and overall survival (OS). *NUSAP1* is involved in cell proliferation and migration and *KIAA0101* participates in cell cycle control and apoptosis [15, 16]. Overexpression of these genes have each been correlated with tumor progression and metastasis [17-19]. Downregulation of *MME* is associated with tumor recurrence and metastasis [20]. Underexpression of *DST*, which produces a cytoskeletal protein, promotes breast cancer progression independently of tumor hormonal status [21].

# Materials and Methods

**Patient population.** Patients with BC were recruited, engaged in informed consent, and enrolled in the study in the Centro de Cáncer de Mama (Breast Cancer Center) of the Hospital San José in Monterrey, Mexico. The Institutional Review Board of the School of Medicine of Tecnologico de Monterrey (CONBIOETICA 19 CEI 011-2016-10-17) authorized the research protocol with the number: P000088-Altru-Pro-CI-CR002. In accordance with the Declaration of Helsinki, informed written consent was obtained from all patients participating in this study. Tissue samples were collected from 54 patients with clinical and/or radiologic diagnosis of BC (tumor size > 2 cm and palpable lymph nodes) from July 2011 to October 2014.

**Neo-adjuvant chemotherapeutic regimens.** Regimens were established according to the clinical stage and the immunohistochemistry of the breast tumors by medical oncologists. They consisted of 4 cycles every 3 weeks of either intravenous cyclophosphamide (500–1500 mg/m2) and doxorubicin (≥40 mg/m2) or intravenous cyclophosphamide (500–1500 mg/m2) and epirubicin (≥60 mg/m2). After receiving either of these regimens, patients received 12 weekly cycles of intravenous paclitaxel (80 mg/m2) administered over 1 hr. In patients who demonstrated drug toxicity, cycles of carboplatin replaced the drug responsible for the toxicity. Subsequently, surgical resection of the breast was performed on each patient. Some patients received selected adjuvant therapy after NCT, as recommended by the attending oncologist. In such cases, selection of the chemotherapeutic drug was made according to individual patient characteristics and clinical guidelines (e.g., trastuzumab and tamoxifen).

**Tumor sample collection.** Two tissue samples were collected from each patient: a biopsy sample (BS) before NCT paired with a surgery sample (SS) collected after completing the cycles of NCT. Thick needle puncture biopsies were obtained using a Bard Magnum 12 Fr gauge needle. Tumor location was marked at diagnosis using the carbon tracking technique [22]. Six to eight tissue cylinders were obtained from each patient. Four samples were used for histopathologic analysis and three samples were preserved in RNAlater solution (Sigma-Aldrich; Burlington, MA) for genomic analysis. The SS were obtained from surgeries for local-regional control (modified radical mastectomy in most of the cases). Tissues were sent to pathology for histopathologic and immunohistochemistry analysis. A 2 × 1 cm piece, marked by the carbon track used during the diagnostic biopsy procedure, was preserved in RNAlater solution for the gene expression analysis.

**Immunohistochemistry and** **tumor-infiltrating lymphocytes.** Samples were obtained from each patient for hematoxylin–eosin staining and immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR), and HER2/neu. The histologic grade of the core needle biopsies was obtained prior to neoadjuvant therapy, using the Bloom–Richardson score [23]. The stage of breast cancer was determined according to the American Joint Committee on Cancer [24]. The assessment of the percentage of tumor-infiltrating lymphocytes (TILs) was performed as per the recommendations of the International TILs Working Group 2014 in breast cancer [25]. A complete methodology for TIL assessment has been previously described [26]. Immunohistochemistry for CD3+, CD4+, and CD8+ were also performed on the coreneedlebiopsies priortoNCT to define lymphocyte immunophenotypes, following the American Society of Clinical Oncology/College ofAmericanPathologistsguidelines [27].

**Treatment Response.** Two pathologists evaluated surgical specimens and assessed tumor response to NCT using the Miller–Payne grading system. For the purposes of this study, a Miller–Payne grade 5 score was considered to be pCR and the remaining scores (including partial pathologic response) were classified to be non-pCR [28].

**RNA isolation and microarrays analysis (expression profiles).** RNA isolation from BS and SS were prepared using RNeasy Fibrous Tissue Mini Kit (Qiagen; Germantown, MA) following manufacturer's instructions. RNA quality was assessed by capillary electrophoresis using the Experion Automated Electrophoresis Station (Bio-Rad; Hercules, CA). Processing, microarray hybridization, and gene expression analysis from the selected RNA samples were conducted using the GeneChip 3' IVT Express Kit (Thermo Fisher Scientific; Waltham, MA) and GeneChip Human Genome U133 Plus 2.0 Array (Applied Biosystems; Santa Clara, CA), according to manufacturers’ instructions and as previously described [29].

**Microarray data processing.** Normalization was performed using robust microarray analysis (RMA). Samples from five patients were removed because they showed clearly different profiles from the others due to abnormal microarray quality controls, leaving 39 patients for this study. Probes with a mean expression < 3 (logarithmic scale as derived from RMA) were also removed from further analysis.

Differential gene expression signature analysis was performed using *t*-test with multiple comparison corrections using the false discovery rate (FDR) method [30]. We considered as positive the probes with a significant *P* value (FDR: *P* < .05). These analyses were completed using the free Applied Biosystems Transcriptome Analysis Console (TAC) 4.0.1 software (Thermo Fisher Scientific).

**Gene network.** An interaction analysis of the selected genes was carried out using the online tool STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) version 11.0 [31]. The combined score was computed by combining the probabilities from the different evidence channels and corrected for the probability of randomly observing an interaction [32].

**Real-time qPCR validation.** To validate microarray data, we selected four genes on the basis of the results of the microarray differential gene expression and the interactome analyses in SS tissues: two that were overexpressed (*MME* and *DST*) and two that were underexpressed (*NUSAP1* and *KIAA0101*). The interactome showed that the selected genes are involved in cell cycle regulation pathways, as will be explained in the results section. *GRAMD1A* was used as an endogenous gene control due to a low variation between samples [29]. Expression analyses were assessed using predesigned hydrolysis probes (*MME*, Hs00153510\_m1; *DST*, Hs00156137\_m1; *NUSAP1*, 150 Hs01006195\_m1; *KIAA0101*, Hs00207134\_m1; *GRAMD1A*, Hs.PT.5840681431) (Thermo Fisher Scientific). Total RNA aliquots used for microarray assays were analyzed through qPCR using the Applied Biosystems QuantStudio 3 Real-Time PCR System (Thermo Fisher). Cycle threshold (*Ct*)means for each gene were used to calculate *dCt* (problem minus endogenous), and *2-dCt* analysis was done using calculated *dCt* for all genes. To compare gene expression of pCR and non-pCR groups, the relative expression *2-dCt* was evaluated from qPCR data from all genes after normalization with *GRAMD1A*. Unpaired *t-*test with Welch’s correction was used to establish differences (*P* value < .05).

**Disease-free survival and overall survival.** Comparison of SS gene expression values with DFS and OS was evaluated in the 39 patients. To evaluate differences in OS, log-rank (Mantel–Cox) test was used for comparison of Kaplan–Meier survival curves using GraphPad Prism Windows version 6.01 (La Jolla, CA). A *P* value ≤ .05 was considered to be significant in all statistical analyses.

For external validation, Kaplan–Meier Plotter ([https://kmplot.com/analysis/)](http://kmplot.com/)) online database [33] was used to analyze the OS correlated to high-versus-low gene mRNA expression levels. The Kaplan-Meier Plotter split the BC patient (*n* = 1402) samples into two groups according to their median mRNA levels. The Affymetrix probe IDs used for the Kaplan–Meier analysis were *KIAA0101*/*PCLAF* 202503\_s\_at and *NUSAP1* 219978\_s\_at.


# Results

**Patients.** There were54 patients who enrolled in the study, but only 44 paired (BS and SS) samples satisfied the RNA quality and quantity standards needed for the microarray analysis. In addition, 5 sets of samples were eliminated because they failed to achieve quality standards, leaving 39 patient sample sets for the final analyses. Demographic and clinical characteristics of the patients are described in Table 1. Only 8 (20.5%) of the 39 patients reached pCR, according to the Miller–Payne grading system.

**Table 1.** Patient demographic and clinic characteristics.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All patients (n = 39)** | | **pCR (n = 8) (20.5%)** | | **non-pCR (n = 31) (71.5%)** | | ***p* value** |
| **Age at diagnosis (years)** | 48 | 26 to 63 | 47 | 38 to 57 | 48 | 26 to 63 | 0.73 |
| **BMI (body mass index, kg/m2)** | 28.21 | 20.78 to 39.65 | 28.4 | 20.78 to 39.65 | 28.17 | 24.84 to 33.07 | 0.88 |
| <25 | 8 | 21.0% | 1 | 12.5% | 7 | 22.6% |  |
| >25 | 28 | 72.0% | 6 | 75.0% | 22 | 71.0% |  |
| No Data | 3 | 7.7% | 1 | 12.5% | 2 | 6.4% |  |
| **Menopause status** |  |  |  |  |  |  |  |
| Pre | 21 | 54.0% | 5 | 62.5% | 16 | 51.6% | 0.88 |
| Post | 18 | 46.0% | 3 | 37.5% | 15 | 41.4% |  |
| **Family history** |  |  |  |  |  |  |  |
| Yes | 19 | 49.0% | 3 | 37.5% | 16 | 51.6% | 0.75 |
| No | 20 | 51.0% | 5 | 62.5% | 15 | 41.4% |  |
| **Diabetes mellitus** |  |  |  |  |  |  |  |
| Yes | 2 | 5.0% | 0 | 0.0% | 2 | 6.5% | 0.87 |
| No | 37 | 95.0% | 8 | 100.0% | 29 | 93.5% |  |
| **Number of children** |  |  | 3.625 |  | 3.161 |  | 0.44 |
| Nulliparous | 4 | 10.0% | 0 | 0.0% | 4 | 12.9% | 0.22 |
| 1 or 2 | 12 | 31.0% | 2 | 25.0% | 10 | 32.3% |  |
| >3 | 23 | 59.0% | 6 | 75.0% | 17 | 54.8% |  |
| **Lactation** |  |  |  |  |  |  |  |
| Yes | 16 | 41.0% | 3 | 37.5% | 13 | 41.9% | 0.97 |
| No | 11 | 28.0% | 2 | 25.0% | 9 | 29.0% |  |
| No data | 12 |  |  |  |  |  |  |
| **Smoking** |  |  |  |  |  |  |  |
| Yes | 5 | 13.0% | 2 | 25.0% | 3 | 9.7% | 0.25 |
| No | 34 | 87.0% | 6 | 75.0% | 28 | 90.3% |  |
|  |  |  |  |  |  |  |  |
| **Clinical stage** |  |  |  |  |  |  |  |
| I | 1 | 3.0% | 1 | 12.5% | 0 | 0.0% | 0.82 |
| II | 19 | 49.0% | 2 | 25.0% | 17 | 54.8% |  |
| III | 19 | 49.0% | 5 | 62.5% | 14 | 45.2% |  |
| **TNM classification** |  |  |  |  |  |  |  |
| T1 | 1 | 2.6% | 1 | 12.5% | 0 | 0.0% | 0.93 |
| T2 | 18 | 46.2% | 1 | 12.5% | 17 | 54.8% |  |
| T3 | 11 | 28.2% | 4 | 50.0% | 7 | 22.6% |  |
| T4 | 9 | 23.1% | 2 | 25.0% | 7 | 22.6% |  |
| N0 | 7 | 17.9% | 2 | 25.0% | 5 | 16.1% |  |
| N1 | 23 | 59.0% | 4 | 50.0% | 19 | 61.3% |  |
| N2 | 9 | 23.1% | 2 | 25.0% | 7 | 22.6% |  |
| M0 | 39 | 100.0% | 8 | 100.0% | 31 | 100.0% |  |
| **IHC markers** |  |  |  |  |  |  |  |
| ER+ | 16 | 41.0% | 2 | 25.0% | 14 | 45.2% | 0.30 |
| ER- | 23 | 59.0% | 6 | 75.0% | 17 | 54.8% |  |
| PR + | 17 | 43.6% | 2 | 25.0% | 15 | 48.4% | 0.23 |
| PR- | 22 | 56.4% | 6 | 75.0% | 16 | 51.6% |  |
| HER2+ | 7 | 17.9% | 5 | 62.5% | 2 | 6.5% | 0.0017\*\* |
| HER2 - | 32 | 82.1% | 3 | 37.5% | 29 | 93.5% |  |
| ki67 | 15.4 | 5 to 70 | 17.14 | 5 to 50 | 14.92 | 2 to 70 | 0.76 |
| **Molecular subtype** |  |  |  |  |  |  |  |
| Luminal A | 10 | 25.6% | 1 | 12.5% | 9 | 29.0% | 0.51 |
| Luminal B | 6 | 15.4% | 0 | 0.0% | 6 | 19.4% |  |
| HER2+ | 7 | 17.9% | 5 | 62.5% | 2 | 6.5% |  |
| Triple negative | 16 | 41.0% | 2 | 25.0% | 14 | 45.2% |  |
| ***NUSAP1*(BS)** |  |  |  |  |  |  |  |
| Overexpressed | 17 | 43.6% | 2 | 25.0% | 15 | 48.4% | 0.426 |
| Underexpressed | 22 | 56.4% | 6 | 75.0% | 16 | 51.6% |  |
| ***KIAA0101*(BS)** |  |  |  |  |  |  |  |
| Overexpressed | 18 | 46.2% | 4 | 50.0% | 14 | 45.2% | >0.9999 |
| Underexpressed | 21 | 53.8% | 4 | 50.0% | 17 | 54.8% |  |
| ***NUSAP1*(SS)** |  |  |  |  |  |  |  |
| Overexpressed | 12 | 30.8% | 0 | 0.0% | 12 | 38.7% | 0.0417\* |
| Underexpressed | 27 | 69.2% | 8 | 100.0% | 19 | 61.3% |  |
| ***KIAA0101*(SS)** |  |  |  |  |  |  |  |
| Overexpressed | 28 | 71.8% | 1 | 12.5% | 24 | 77.4% | 0.0003\*\*\* |
| Underexpressed | 11 | 28.2% | 7 | 87.5% | 4 | 12.9% |  |

**Gene expression profile analysis.** The following comparisons were made between BS and SS gene expression data in pCR and non-pCR patients to assess the gene expression modifications induced by NCT: pCR-BS vs pCR-SS (Supplementary Figure 1), non-pCR-BS vs non-pCR-SS (Supplementary Figure 2), pCR-BS vs non-pCR-BS (Supplementary Figure 3), and pCR-SS vs non-pCR-SS (Figure 1). Of these comparisons, significant unsupervised sample clustering (pCR vs non-pCR) was only achieved in the last one, in SS (Figure 1).



**Figure 1. Unsupervised sample clustering (heat map) of differential gene expression in SS (pCR vs non-pCR).** Blue areas represent low gene expression, while red represents high gene expression. The top row separates the non-pCR (blue) and pCR (red) patients. Each column represents a different sample and each row, a single probe. Official gene or probe symbols are displayed at the right-side margin.

From the comparisons of gene expression profiles, sets of genes were generated with which Venn diagrams and interactome networks were constructed to facilitate the selection of candidate genes for survival analyses. The first comparison assessed changes induced by NCT in samples of patients achieving pCR (BS = 8 vs SS = 8). A profile of 21 probes representing 14 genes was found (fold change (FC) = +3, FDR *P* value < .05) (Figure 2A). It showed that 3 genes were overexpressed (*TOP2A*,*RRM2*, and *CDKN3*) and 11 were downregulated (*EGR2*, *ADAMTS5*, *JUN*, *APOLD1*, *DUSP1*, *CYR61*, *ATF3*, *EGR1*, *PTGS2*, *RGS1*,and *FOSB*) (Supplementary Figure 1). These genes were enriched in pathways regulating cell death, apoptosis, morphogenesis, and circadian processes (Figure 2A). Likewise, the study of the non-pCR subset of patients (BS = 31 vs SS = 31) identified four overexpressed genes in SS biopsies (*NAMPT*, *DUSP1, RGS1*, and *FOS*) (FC = ±3, FDR *P* value < .05) (Figure 2B and Supplementary Figure 2). Gene Network by STRING added 10 nodes (proteins) to show a network around the 4 main genes on this gene profile. Pathways enriched by these genes were associated with response to ionizing radiation, metal ions, lipids, organonitrogen compounds, and drugs (Figure 2B). Comparisons between pCR and non-pCR were made in the BS (Figure 2C and Supplementary Figure 3). Immunologic pathways were enriched in this comparison (IgG binding, and MHC class II receptor activity), but these genes barely interacted.

A significant unsupervised sample clustering was only achieved in the last comparison of SS group (Figure 1 and Figure 2D). This pCR (*n* = 8) vs non-pCR (*n* = 31) comparison revealed a profile of 55 probes corresponding to 43 genes (FC = ±3, FDR *P* value < .0298) (Figure 1D). In patients with pCR, 30 genes were overexpressed (*ABCA9*, *ABCB5*, *ADAMTS5*, *ANKRD29*, *ARHGAP20*, *ASPA*, *CCDC178*, *CCDC8*, *CD300LG*, *CLDN5*, *CNN1*, *COL6A6*, *DST*, *FAM196B*, *FHL1*, *FIGF*, *PIR-FIGF*, *GAS1RR*, *GPRASP1*, *HAS3*, *ITIH5*, *LRFN5*, *LRRN4CL*, *MME*, *OXTR*, *PGM5*, *PRRG3*, *SCN3A*, *SCN4B*, *SDPR*, and *TUBB2B*), whereas 13 were downregulated (*ATAD2*, *AURKA*, *CCNB1*, *HIST1H2BD*, *HN1*, *KIAA0101*, *NUSAP1*, *PMAIP1*, *RRM2*, *SORD*, *TPD52*, *UBE2C*, and *UBE2T*). Among proteins of this gene profile, 3 were enriched for mitotic nuclear division and 5 for the anaphase promoting complex–dependent catabolic process.

|  |
| --- |
| A |
| B |
| C |
| D |

**Figure 2. Comparisons between BS, SS, and pathologic responses.** For each component in the figure, intersections of differentially expressed gene sets are shown in Venn diagrams on the left side and protein interaction networks are shown on the right side. Gene ontology (GO) tables are shown at the bottom. **A.** Genetic profiles for BS (green) and SS (red) in pCR patients showing differential expression of 14 genes involved in cell death, morphogenesis, and circadian processes. **B.** Genetic profiles for BS (yellow) and SS (blue) in non-pCR patients, showing 4 overexpressed genes involved in response to ionizing radiation, metal ions, lipids, and drugs. **C.** Genetic profiles for pCR and non-pCR patients in BS showing 21 differentially expressed genes involved in the immune response. **D.** Gene profiles for pCR and non-pCR patients in SS, showing 43 differentially expressed genes involved in the regulation of mitotic division. BS, biopsy sample (pretreatment); SS, surgical sample (post-treatment); pCR, pathologic complete response; non-pCR, incomplete pathological response; PPI, *P* value of protein–protein interaction enrichment.

**Gene network.** The online tool STRING [31] was used to investigate interactions among genes identified as differentially expressed in each comparison. The value of the interaction network was significant (protein–protein interaction enrichment *P* value (PPI): 2.26 × 10−10), meaning that these proteins have more interactions among themselves than what would be expected from a random set of proteins of similar size drawn from the genome (Figure 2). According to the protein interaction analysis, the genes *AURKA*, *CCDC8*, *CCNB1*, *NUSAP1*, and *UBE2C* are involved in the regulation of nuclear division during mitosis, whereas *AURKA*, *CCNB1*, and *UBE2C* are part of the anaphase promoting complex–dependent catabolic process.

# qPCR Validation. Four genes (*DST*, *MME*, *NUSAP1*,and *KIAA0101*/*PCLAF*) were selected to validate the microarrays by qPCR as explained in the Methods section. The remaining DNA from the tissue sample was scarce; therefore, only 31 (pCR = 5, non-pCR = 26) of 39 samples had enough quality and quantity of total RNA to perform qPCR validation analysis. Supplementary Figure 4 shows the box plot of *NUSAP1* and *KIAA0101* expression by qPCR (Figures 4A and 4B) and by microarray (Figures 4C and 4D). A similar analysis was made for *DST* and *MME* expression by qPCR (Figures 4E and 4F) and by microarray (Figures 4G and 4H). This qPCR analysis corroborated the expression patterns of these differentially expressed genes.

***NUSAP1* and *KIAA0101* gene expression.** In the subset of patients achieving pCR, *NUSAP1* and *KIAA0101* gene expressions were higher in the BS than in the SS samples (two-way ANOVA, F = 22.12, *P* value = .0053) (Figure 3A and 3C), whereas there was no significant difference in the expression values in the non-pCR groups (two-way ANOVA, F = 1.246, *P* value = .2739) (Figure 3B and 3D). It is important to note that the expression of *NUSAP1* after NCT was significantly higher in luminal B tumors than in the rest of the histologic subtypes*.* (F test = 4.88, *P* = 0.0063) (Supplementary Figure 5).

|  |  |
| --- | --- |
| **A** | **B** |
| **C** | **D** |

**Figure 3. *NUSAP1* and *KIAA0101* gene expression based on microarrays data.** **A** and **B**: *NUSAP1* gene expression in BS and SS in pCR (A) and non-pCR (B) patients, respectively. **C** and **D**: *KIAA0101* gene expression in BS and SS in pCR (C) and non-pCR (D) patients, respectively. Blue lines and triangles, triple-negative molecular subtype; red lines and squares, luminal A/B molecular subtype; green lines and circles, HER2 molecular subtypes. Two-way ANOVA was performed and a *P* value < .05 was considered to be significant.

**Expression of *NUSAP1* and *KIAA0101* and response to treatment.** Response to NCT was considered the primary response variable and was evaluated using the Miller–Payne grading system. The association between the *NUSAP1* and *KIAA0101* genes with response to treatment was tested. The expression of *NUSAP1* and *KIAA0101* after NCT were inversely associated with pCR, implying that the downregulation of these genes had a favorable effect for the patient, as shown in Table 2 (*NUSAP1*: OR = 0.0, 95% IC = 0.00-0.99, *P* = .0417 ; *KIAA0101*: OR = 0.02, 95% IC = 0.002-0.243, *p* = 0.0003\*\*\*).

**Table 2. *NUSAP1* and *KIAA0101* and response to treatment**

|  |  |  |
| --- | --- | --- |
|  | ***NUSAP1*** | ***KIAA0101*** |
| **OR** | 0.00 | 0.02 |
| **95% IC** | 0.000 to 0.9915 | 0.002068 to 0.2430 |
| **p value** | 0.0417\* | 0.0003\*\*\* |
| **Sensitivity** | 0.00 | 0.13 |
| **95% IC** | 0.000 to 0.3244 | 0.6412 to 47.09% |
| **Specificity** | 0.61 | 0.14 |
| **95% IC** | 0.4382 to 0.7627 | 5.699 to 31.49% |
| **Positive Predictive Value** | 0.00 | 0.04 |
| **95% IC** | 0.000 to 0.2425 | 0.2052 to 19.54% |
| **Negative Predictive Value** | 0.70 | 0.36 |
| **95% IC** | 0.5152 to 0.8415 | 15.17 to 64.62% |
| **Likelihood Ratio** | 0.00 | 0.15 |

**Tumor infiltrating lymphocytes.** *NUSAP1* and *KIAA0101* expression versuslymphocyte immunophenotypes and TILs were evaluated priortoNCT (Table 3). There were no correlations among TILsand *NUSAP1* and *KIAA0101* expression levels (*NUSAP1*: r = 0.10, 95% IC = −0.39-0.25, *P* =.65; *KIAA0101*: r = −0.07, 95% IC = 0.85-0.96, *P* = .54). Representative images of TILs evaluation are shown in Supplementary Figure 6.

**Table 3.** **TILs correlation**

|  |  |  |  |
| --- | --- | --- | --- |
| **TILs correlation** |  |  |  |
| **N=39** | **r** | **95% IC** | ***p value*** |
| ***NUSAP1* and TILS%** | 0.10 | -0.39 to 0.25 | 0.65 |
| ***KIAA0101* and TILS%** | -0.07 | -0.22 to 0.40 | 0.54 |
| ***NUSAP1* and *KIA0101*** | 0.92 | 0.85 to 0.96 | 2.22 E-16 |

**Disease-free survival and overall survival.** Patients were followed up for 46.5 months on average (SD = 20.34; range = 5.1-79.2 months). Supplementary Figure 7 shows that HER2+ patients have better OS, although significance levels were not reached (*P* value = .0732). *NUSAP1* and *KIAA0101* expression patterns were compared against tumor relapse for DFS and death due to BC for OS. Regarding DFS, the number of relapses was significantly higher in patients with overexpression of *NUSAP1* in the SS (38%, log-rank (Mantel–Cox) test, χ2 = 4.665, *P* value = .0308) (Figure 4A). Likewise, higher levels of *NUSAP1* gene expression in the SS were also associated with decreased OS, with a reduction from 84% to 50% (log-rank (Mantel–Cox) test, χ2 = 5.198, *P* value = .0226) (Figure 4C). Similarly, *KIAA0101* gene overexpression negatively affected OS, with a reduction from 80% to 71% (log-rank (Mantel–Cox) test, χ2 = 0.4024, *P* value = .5258 (Figure 4B and D). Comparisons of gene expression patterns from BS failed to classify responders and nonresponders. OS results were replicated by analyzing public data on 1402 patients from the Kaplan–Meier Plotter website ([http://kmplot.com](http://kmplot.com/)). Low levels of *NUSAP1* and *KIAA0101* were associated with greater OS (log-rank HR = 1.82, CI = 1.46-2.26, *P* value = 6.2 × 10−8 and log-rank HR = 1.47, CI = 1.19-1.82, *P* value = .00039, respectively) (Figures 4E and 4F, also respectively).

|  |  |
| --- | --- |
| **A** | **B** |
| **C** | **D** |
| **E** | **F** |

**Figure 4. Disease-free survival and overall survival against *NUSAP1* and *KIAA0101* gene expression profiles.** **A and B:** DFS curves considering *NUSAP1* and *KIAA0101* gene expression profiles after NCT (SS), respectively. Blue lines, underexpression; red lines, overexpression. **C and D:** OS curves considering *NUSAP1* and *KIAA0101* gene expression profiles after NCT (SS), respectively. Blue lines, underexpression; red lines, overexpression. **E and F:** OS curves considering *NUSAP1* and *KIAA0101* expression profiles from the Kaplan-Meier Plotter website (http://kmplot.com), respectively. Black lines, underexpression; red lines, overexpression.

# Discussion

Omics technologies, global gene expression analyses in particular, have had a great impact on the understanding of BC biology, the classification of pathologic subtypes, the design of prognostic algorithms and, most importantly, the discovery and implementation of new and more effective therapies to control this disease [34]. All of these advances have positioned BC as one of the archetypal entities in precision medicine. Improvements in the selection of therapies based on the different molecular subtypes of BC have yielded higher DFS and prolonged OS. However, after a certain time of treatment, a high proportion of patients who do not fully respond to the assigned therapy has been observed. Therefore, just as it is important to choose the appropriate therapeutic regimen at the beginning of treatment, it is also a challenge to define the most appropriate therapies beyond the first line, especially in pretreated patients [35]. Analysis of the molecular response to NCT may offer an opportunity to define prognoses and alternative therapies in patients with a BC diagnosis [12].

In this work, we studied gene expression profiles obtained through unsupervised cluster analysis of BS and SS tissues in patients with PCR and non-PCR after NCT. After analyzing the different expression profiles, when combining sample types (BS or SS) and the presence of lack of response to NCT, the only analysis that classified pCR from non-pCR patients was the comparison of expression profiles in SS tissues. This analysis unveiled 30 overexpressed and 13 underexpressed genes in treated tumors (Supplementary Table 1). These genes are mainly involved in the regulation of nuclear division during mitosis, such as the catabolic process dependent on the anaphase promoting complex. Deregulated gene expression of some of these genes has been reported in BC. For example, *CCNB1, KIAA0101, NUSAP1, RRM2, UBE2C*, and *UBE2T* alterations are part of a gene signature identified in BC tumorigenic processes in young women from the Middle East [36]. Moreover, *CCNB1*, *RRM2*, and *UBE2C* genes are included in the PAM50 signature as elements for the molecular classification of BC lesions [37]. However, there are no reports of a genetic signature to predict BC response after NCT.

We selected 4 genes were for qPCR validation analyses based on the results of the differential gene expression study and SS interactome analysis: 2 that were overexpressed (*MME* and *DST*) and two that were underexpressed (*NUSAP1* and *KIAA0101*). These validation studies corroborated the expression patterns observed in the microarray analyses. The gene expression levels of *NUSAP1* and *KIAA0101* were more discriminating in the qPCR analyses and, for this reason, they were chosen to perform the DSF and OS studies (Supplementary Figure 4).

DSF and OS studies based on expression levels in SS demonstrated that low *NUSAP1* expression was associated with better DFS. Similarly, underexpression of *NUSAP1* and *KIAA0101* were associated with increased OS (Figure 4 A-F).

The most important observation of this study is that the pCR achieved with the NCT regimens (cyclophosphamide/doxorubicin or cyclophosphamide/epirubicin) is associated with a significant decrease in the gene expression levels of *NUSAP1* and *KIAA0101*. This is consistent with the fact that the expression of these genes is involved in cell division processes and may modulate cancer progression, as will be discussed here later. As reported, this clinical response presupposes better DFS and OS [11]. Furthermore, higher expression levels of these same genes in the tumor biopsy before treatment (BS) were associated with poorer survival, indicating that these genes are potential predictors of survival in diagnostic biopsies.

The study suggests that the HER2+ subtype responds favorably to NCT (*P* value = .017) and that the luminal B subtype responds poorly, with no observed significant difference. Profile expression patterns of *NUSAP1* and *KIAA101* genes in different molecular subtypes of BC after NCT showed that *NUSAP1* was overexpressed in luminal B tumors compared to luminal A, HER2+, and triple-negative subtypes (Figure 3 and Supplementary Figure 5). Colak et al reported overexpression of *NUSAP1* and *KIAA0101* in ductal in situcarcinoma and invasive ductal carcinoma when compared to normal age-matched controls [36]. TILs have been reported to modulate the NCT response in breast cancer [38]. In this study, no correlations were observed between TIL counts and the expression of *NUSAP1* and *KIAA0101* in BS tissues from patients with and without PCR.

The protein codified by *KIAA0101* (the gene also known as *PCLAF*), PCNA-associated factor, binds the PCNA protein, acts as a regulator of the number of centrosomes, and is involved in DNA repair during DNA replication [15]. Overexpressed *KIAA0101* has been also associated with decreased survival in BC patients [15], but not with the pathologic response to NCT. *NUSAP1* gene expression levels showed a remarkable inverse correlation with survival (Figures 4A, 4C, and 4D). This gene encodes for nucleolar and spindle-associated protein 1, which binds to chromatin and microtubules and is critical for the cytokinesis spindle assembly during mitosis [16]. *NUSAP1* overexpression has been reported in bladder, cervical, colon, liver, lung, prostate, kidney, and breast cancers, glioblastoma, and oral squamous cell carcinoma [39-43]; multiple studies have correlated its overexpression with poor prognosis [15, 40, 41, 44-48]. Zhang et al. demonstrated that downregulation of *NUSAP1* suppressed proliferation, migration, and invasion of MCF-7 cells by disturbing the regulation of *CDK1* and *DLGAP5* and increased susceptibility to epirubicin [41]. Our findings are similar to those of Qiu et al, who reported higher *NUSAP1* expression in tumor than in adjacent healthy tissue and an inverse correlation between *NUSAP1* expression and OS in BC patients. These findings were corroborated in a BALB/c-nu mouse model in which they determined the involvement of *NUSAP1* in tumor proliferation, migration, and invasion [18]. Finally, *NUSAP1* has been proposed as a carcinogenic element whose overexpression would help tumor progression in triple-negative BC cells, participating in the epithelial-mesenchymal transition and the Wnt/β-catenin pathways [17].

Our findings, together with those previously reported, indicate that these two genes may be prognostic genetic markers in BC but, at the same time, potential therapeutic targets. The proteins from *NUSAP1* (NUSAP1, or nucleolar and spindle-associated protein 1) and *KIAA0101*(PCNA-associated factor) are involved in BCRA1-mediated DNA repair. NUSAP1 protein increases BRCA1 protein expression [49], whereas PCNA-associated factor regulates the number of centrosomes by interacting with BRCA1 [15]. Since the biological roles of the *NUSAP1* and *KIAA0101* genes involve cell cycle pathways, patients with elevated transcription levels of these genes may benefit from chemotherapeutic drugs interfering with BRCA1, such as platinum derivatives. *NUSAP1* overexpression could also be treated with galiellalactone, a fungal metabolite with antitumor and anti-inflammatory properties. Galiellalactone downregulates *NUSAP1* in DU 145 cells by targeting the NF-κB and STAT3 pathways, inducing cell cycle arrest [50]. Another option to target *NUSAP1* overexpression is the antitumor compound isopicrinine, isolated from *Rhazya stricta*, an inhibitor of the microtubule assembly [51].

# Finally, decreased expression of *NUSAP1* seems to sensitize osteosarcoma cells to paclitaxel, as *NUSAP1* interacts with the RanBP2-RanGAP1-UBC9 SUMO E3 ligase complex, allowing for accurate chromosomal segregation [52]. *NUSAP1* knockdown has been observed to potentiate paclitaxel-induced apoptosis in oral squamous cell carcinoma [53].

# In summary, our studies show significant results of downregulation of *NUSAP1* and *KIAA0101* and overexpression of *MME* and *DST* in SS, predicting pCR. BS data do not reach significance, but this correlation is also registered. On the contrary, the data suggest that overexpression of *NUSAP1* and *KIAA0101* are associated with decreased DFS. This information could be useful to implement a second line of treatment or more aggressive regimes.

# It is important to highlight some limitations of this study. The first is that the sample is small, but the NCT schemes and sampling were standardized for most study participants. The sample also has an overrepresentation of triple-negative BC because the NCT program prioritizes patients with this tumor subtype.

# Conclusions

Downregulation of *NUSAP1* and *KIAA0101* in SS after NCT were associated with favorable therapeutic response and prognosis in BC. Overexpression of these two genes opens the possibilities for personalized therapies for patients who do not respond adequately to NCT.

**Data Availability.** The dataset generated and analyzed during the current study can be available from the corresponding author on reasonable request.

# Declaration of interests. None.

**Funding Statement.** This work was supported by Tecnologico de Monterrey [Convocatoria para el Desarrollo de Protocolos de Investigación Clínica sobre Temas Prioritarios para la Escuela de Medicina y Ciencias de la Salud 2018] and the Mexican National Council of Science and Technology (CONACYT) [SALUD 2011: 162301, 2017 APN: 4496].

**Acknowledgements.** This manuscript is original; a previous version of this manuscript was uploaded to Research Square and can be found at https:/[/www](http://www.researchsquare.com/article/rs-).[researchsquare.com/article/rs-](http://www.researchsquare.com/article/rs-) 49283/v1, but is not currently being considered for publication elsewhere. We thank Tecnologico de Monterrey, CONACYT, and the Center for Research and Development in Health Sciences (CIDICS) from the Autonomous University of Nuevo León (UANL).

# Authors’ contributions

Gerardo I. Magallanes-Garza: conceptualization, methodology, investigation, writing (original draft), and writing (review and editing), and visualization; Sandra K. Santuario-Facio: conceptualization, methodology, investigation, writing (original draft), and writing (review and editing, and visualization; Arlina F. Varela-Varela: validation and investigation; Servando Cardona-Huerta: conceptualization, investigation, and writing (review and editing); Pablo Ruiz-Flores: validation and investigation; Jorge Haro-Santa-Cruz: validation and investigation; Yadira X. Perez-Paramo: validation and investigation. Gabriela S. Gomez-Macias: validation and investigation; Daniel Davila-Gonzalez: data curation and visualization; Javier Valero-Gomez: validation and investigation; Gissela Borreo-Soto: validation and investigation; Augusto Rojas-Martinez: writing (original draft), writing (review and editing), and visualization; Rocio Ortiz-Lopez: conceptualization, methodology, writing (original draft), and writing (review and editing), supervision, project administration, funding acquisition.

**Ethics approval and consent to participate.** The Institutional Review Board from the School of Medicine of Tecnologico de Monterrey (CONBIOETICA 19 CEI 011-2016-10-17) authorized the research protocol with the number: P000088-Altru-Pro-CI-CR002. In accordance with the Declaration of Helsinki, informed written consent was obtained from all patients participating in this study.

# Supplementary Material

Supplementary material shows three heatmaps of comparisons with groups of samples (BS and SS). Supplementary materials also include qPCR validations plots and expression levels of *NUSAP1* according to the molecular subtype after the NCT. Finally, a supplementary table contains the differently expressed probes in pCR and non-pCR surgical samples.

**Supplementary Figure 1. Heatmap of pCR patients (BS vs SS).** Blue areas, low gene expression; red areas, high gene expression. Top row: SS tissues are denoted by the blue header (left heatmap) and SS tissues; are denoted by the red header (right heatmap). Each individual column represents a different patient sample and each row, a single probe. Official symbols for gene or probe identification are displayed along the right margin.

**Supplementary Figure 2. Heatmap of non-pCR patients (BS vs SS).** Blue areas, low gene expression; red areas, high gene expression. Top row, BS tissues are denoted in each column by a blue header and SS tissues by a red header. Each column represents a different sample, and each row is for a single probe. Official symbols for gene or probe identification are displayed along the right margin.

**Supplementary Figure 3. BS tissue comparisons between non-pCR (*n* = 31) and pCR (*n* = 8).** Profile of 30 probes representing 21 genes (11 overexpressed and 10 underexpressed in pCR, FC: +2, *P* value ≤ .01). Blue areas, low gene expression; red areas, high gene expression. Top row, non-pCR patients are denoted in each column by a blue header and pCR patients by a red header. Each column represents a different patient sample and each row, a single probe. Official symbols for gene or probe identification are displayed along the right margin.

**Supplementary Figure 4. Box plots showing validation by qPCR (*NUSAP1*, *KIAA0101*, *DST*,and *MME*)**. **A and B** represent expression levels of *NUSAP1* and *KIAA0101*, respectively, as analyzed by qPCR. **C and D** represent expression levels of *NUSAP1* and *KIAA0101*,respectively, according to the expression signal after normalization with robust multiarray analysis (RMA) from the microarray data. **E and F** represent qPCR analysis of expression of *DST* and *MME*, respectively. **G and H** represent expression levels of *DST* and *MME*, respectively, according to the expression signal after normalization with RMA from the microarray data. Blue lines, the pCR patient group; red lines, the non-pCR patient group. Unpaired *t*-test with Welch’s correction was used for comparisons.

**Supplementary Figure 5. Expression levels of *NUSAP1* according to the molecular subtype after NCT (SS).** LA, luminal A; LB, luminal B; TN, triple negative. One-way ANOVA and the Holm–Sidak multiple comparisons test were used for comparisons.

**Supplementary Figure 6. Microscopic evaluation of TILs.** **A** Low TILs, 10×. Fibrous stroma is observed between the tumor cells, with little lymphoplasmacytic infiltrate at a percentage of 5%. **B** Moderate TILs, 10×. Moderate lymphoplasmacytic infiltrate is seen in the tumoral stroma at a percentage of 30%. **C** High TILs, 10×. Dense lymphoplasmacytic infiltrate observed in the stroma between the neoplastic cells in the upper left area at a percentage of 80%.

**Supplementary Figure 7.** OS according to the molecular subtype after NCT (SS). LA, luminal A; LB, luminal B; TN, triple negative. Log-rank (Mantel–Cox) test was used for comparisons.

# Supplementary Table 1. Probes differentially expressed in pCR and non-pCR surgical samples.

**References**

1. Villarreal-Garza, C., et al., *Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy.* Breast Cancer Res Treat, 2016. **157**(2): p. 385-394.

2. Reynoso-Noveron, N., et al., *Clinical and Epidemiological Profile of Breast Cancer in Mexico: Results of the Seguro Popular.* J Glob Oncol, 2017. **3**(6): p. 757-764.

3. Haque, W., et al., *Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy.* Breast Cancer Res Treat, 2018. **170**(3): p. 559-567.

4. van de Vijver, M.J., et al., *A gene-expression signature as a predictor of survival in breast cancer.* N Engl J Med, 2002. **347**(25): p. 1999-2009.

5. Paik, S., et al., *A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.* N Engl J Med, 2004. **351**(27): p. 2817-26.

6. Sotiriou, C., et al., *Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.* J Natl Cancer Inst, 2006. **98**(4): p. 262-72.

7. Vera-Ramirez, L., et al., *Transcriptional shift identifies a set of genes driving breast cancer chemoresistance.* PLoS One, 2013. **8**(1): p. e53983.

8. Gonzalez-Angulo, A.M., et al., *Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer.* Clin Cancer Res, 2012. **18**(4): p. 1109-19.

9. Savci-Heijink, C.D., et al., *Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.* BMC Cancer, 2017. **17**(1): p. 755.

10. Foukakis, T., et al., *Immune gene expression and response to chemotherapy in advanced breast cancer.* Br J Cancer, 2018. **118**(4): p. 480-488.

11. Sasanpour, P., et al., *Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients.* Asian Pac J Cancer Prev, 2018. **19**(9): p. 2423-2427.

12. von Minckwitz, G., et al., *Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.* J Clin Oncol, 2012. **30**(15): p. 1796-804.

13. Masuda, N., et al., *Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.* N Engl J Med, 2017. **376**(22): p. 2147-2159.

14. Huang, M., et al., *Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.* Cancer Res, 2020. **80**(24): p. 5427-5434.

15. Kais, Z., et al., *KIAA0101 interacts with BRCA1 and regulates centrosome number.* Mol Cancer Res, 2011. **9**(8): p. 1091-9.

16. Ribbeck, K., et al., *NuSAP, a mitotic RanGTP target that stabilizes and cross-links microtubules.* Mol Biol Cell, 2006. **17**(6): p. 2646-60.

17. Sun, L., et al., *Overexpression of NuSAP1 is predictive of an unfavourable prognosis and promotes proliferation and invasion of triple-negative breast cancer cells via the Wnt/beta-catenin/EMT signalling axis.* Gene, 2020. **747**: p. 144657.

18. Qiu, J., et al., *NUSAP1 promotes the metastasis of breast cancer cells via the AMPK/PPARgamma signaling pathway.* Ann Transl Med, 2021. **9**(22): p. 1689.

19. !!! INVALID CITATION !!! [17-19].

20. Li, M., et al., *Membrane Metalloendopeptidase (MME) Suppresses Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) by Inhibiting FAK-RhoA Signaling Axis.* Am J Pathol, 2019. **189**(7): p. 1462-1472.

21. Jain, P.B., et al., *The spectraplakin Dystonin antagonizes YAP activity and suppresses tumourigenesis.* Sci Rep, 2019. **9**(1): p. 19843.

22. Svane, G., *A stereotaxic technique for preoperative marking of non-palpable breast lesions.* Acta Radiol Diagn (Stockh), 1983. **24**(2): p. 145-51.

23. Bloom, H.J. and W.W. Richardson, *Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.* Br J Cancer, 1957. **11**(3): p. 359-77.

24. Cancer, A.J.C.o., *The New Edition (7th) AJCC Staging System for Breast Cancer.* 2010.

25. Salgado, R., et al., *The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.* Ann Oncol, 2015. **26**(2): p. 259-71.

26. Gomez-Macias, G.S., et al., *Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization.* Oncol Lett, 2020. **20**(5): p. 140.

27. Hammond, M.E., D.F. Hayes, and A.C. Wolff, *Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.* J Clin Oncol, 2011. **29**(15): p. e458.

28. Ogston, K.N., et al., *A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.* Breast, 2003. **12**(5): p. 320-7.

29. Santuario-Facio, S.K., et al., *A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy.* Mol Med, 2017. **23**: p. 101-111.

30. Benjamini, Y., et al., *Controlling the false discovery rate in behavior genetics research.* Behav Brain Res, 2001. **125**(1-2): p. 279-84.

31. Szklarczyk, D., et al., *STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets.* Nucleic Acids Res, 2019. **47**(D1): p. D607-D613.

32. von Mering, C., et al., *STRING: known and predicted protein-protein associations, integrated and transferred across organisms.* Nucleic Acids Res, 2005. **33**(Database issue): p. D433-7.

33. Gyorffy, B., et al., *An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.* Breast Cancer Res Treat, 2010. **123**(3): p. 725-31.

34. Scimeca, M., et al., *Precision medicine in breast cancer: From biological imaging to artificial intelligence.* Semin Cancer Biol, 2021. **72**: p. 1-3.

35. Lorusso, V., A. Latorre, and F. Giotta, *Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer.* J Oncol, 2020. **2020**: p. 9645294.

36. Colak, D., et al., *Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.* PLoS One, 2013. **8**(5): p. e63204.

37. Bastien, R.R., et al., *PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.* BMC Med Genomics, 2012. **5**: p. 44.

38. Sarradin, V., et al., *Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.* Breast Cancer Res, 2021. **23**(1): p. 61.

39. Kretschmer, C., et al., *Identification of early molecular markers for breast cancer.* Mol Cancer, 2011. **10**(1): p. 15.

40. Liu, R., C.X. Guo, and H.H. Zhou, *Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen.* Cancer Biol Ther, 2015. **16**(2): p. 317-24.

41. Zhang, X., et al., *Nucleolar and Spindle Associated Protein 1 (NUSAP1) Inhibits Cell Proliferation and Enhances Susceptibility to Epirubicin In Invasive Breast Cancer Cells by Regulating Cyclin D Kinase (CDK1) and DLGAP5 Expression.* Med Sci Monit, 2018. **24**: p. 8553-8564.

42. Yang, Z., et al., *Hepatitis B virus X protein enhances hepatocarcinogenesis by depressing the targeting of NUSAP1 mRNA by miR-18b.* Cancer Biol Med, 2019. **16**(2): p. 276-287.

43. Chen, L., et al., *High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer.* PLoS One, 2015. **10**(10): p. e0140572.

44. Head, J.R., P.C. MacDonald, and M.L. Casey, *Cellular localization of membrane metalloendopeptidase (enkephalinase) in human endometrium during the ovarian cycle.* J Clin Endocrinol Metab, 1993. **76**(3): p. 769-76.

45. Qian, Z., et al., *Prognostic value of NUSAP1 in progression and expansion of glioblastoma multiforme.* J Neurooncol, 2018. **140**(2): p. 199-208.

46. Yu, Z., et al., *[Expression of NUSAP1 and its relationship with prognosis in non-small cell lung cancer].* Zhonghua Zhong Liu Za Zhi, 2019. **41**(7): p. 522-526.

47. Gordon, C.A., et al., *NUSAP1 promotes invasion and metastasis of prostate cancer.* Oncotarget, 2017. **8**(18): p. 29935-29950.

48. Yang, H., et al., *A four-gene signature for prognosis in breast cancer patients with hypermethylated IL15RA.* Oncol Lett, 2019. **17**(5): p. 4245-4254.

49. Kotian, S., et al., *NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels.* Cancer Biol Ther, 2014. **15**(5): p. 533-43.

50. Garrido-Rodriguez, M., et al., *SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone.* J Proteomics, 2019. **193**: p. 217-229.

51. Gu, Z. and A. Zakarian, *Total synthesis of rhazinilam: axial to point chirality transfer in an enantiospecific Pd-catalyzed transannular cyclization.* Org Lett, 2010. **12**(19): p. 4224-7.

52. Mills, C.A., et al., *Nucleolar and spindle-associated protein 1 (NUSAP1) interacts with a SUMO E3 ligase complex during chromosome segregation.* J Biol Chem, 2017. **292**(42): p. 17178-17189.

53. Okamoto, A., et al., *Down-Regulation of Nucleolar and Spindle-Associated Protein 1 (NUSAP1) Expression Suppresses Tumor and Cell Proliferation and Enhances Anti-Tumor Effect of Paclitaxel in Oral Squamous Cell Carcinoma.* PLoS One, 2015. **10**(11): p. e0142252.